申请人:Janssen Pharmaceutica NV
                            
                            
                                公开号:US20220332713A1
                            
                            
                                公开(公告)日:2022-10-20
                            
                            Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
Wherein R
1
, R
2
, R
2a
, R
3
, R
3a
, R
4
, and R
4a
are defined herein.